Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
coxsackievirus a21 + ipilimumab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intralesional, Intravenous
01
Overview
**coxsackievirus a21 + ipilimumab** is a combination investigational immunotherapy consisting of an oncolytic virus (Coxsackievirus A21, CVA21; branded as CAVATAK or V937) and a monoclonal antibody immune checkpoint inhibitor (ipilimumab; branded as Yervoy)[1][3][5][7]. CVA21 is a bio-selected strain of coxsackievirus A21 that selectively infects and lyses cancer cells, also acting to stimulate immune-cell infiltration and upregulate interferon-gamma response and immune genes[3][7]. Ipilimumab is a human monoclonal antibody targeting CTLA-4, inhibiting negative regulation of T cell activation, thereby boosting anti-tumor immunity[8]. The combination is being evaluated for the treatment of advanced melanoma and metastatic uveal melanoma, where CVA21 is typically administered intralesionally or intravenously, while ipilimumab is received intravenously[1][5][7].
- Brand names
- CAVATAK + YERVOY
- Other names
- coxsackievirus a21 + ipilimumabintralesional CVA21 + intravenous ipilimumab
02
Targets
ICAM1 (Intercellular Adhesion Molecule 1)CD55 (Complement decay-accelerating factor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on coxsackievirus a21 + ipilimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on coxsackievirus a21 + ipilimumab.